Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00425711 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Acamprosate in Driving Under the Influence (DUI) Court Participants

StatusTerminated
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Jul 26, 2012, no change to tracked fieldsv7-v8
  2. Trial status: Active, Not Recruiting to Terminated Sponsor's reason: Recruitment barriers.
    • Enrollment target: estimated 30 to confirmed 4
    v6
  3. Eligibility criteria revised
    • Study title expanded, about 2 words
    v5
  4. Trial status: Recruiting to Active, Not Recruiting
    • Eligibility criteria shortened, about 10 words
    • Study description shortened, about 27 words
    • Study site revised
    v4
  5. Primary and study completion dates: Dec 2009
    • Secondary endpoints revised (7)
    • Site contact updated
    • Study arms: 0 to 1
    v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Acamprosate will be given to approximately 30 DUI Court participants for 3 months and outcomes will be monitored. The hypothesis is that acamprosate will be safe and well-tolerated and that subjects' craving and other symptoms related to addiction will improve over time.
Trial Details
NCT Number NCT00425711
Lead Sponsor University of Oklahoma
Collaborators: Forest Laboratories
Conditions
(from sponsor)		 Alcohol Dependence
Related terms Alcoholism, Driving Under the Influence
Enrollment 4 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov